Lonza Pharma & Biotech is reported to be expanding its operations. The company is buying a Swiss facility that Novartis has been using to produce drug vials. The move is described in the article as part of Lonza's expansion plans. The provided excerpt includes no revenue, user, or other operating metrics for Lonza. The same headline also references an unrelated $14 million Series B led by IQVIA, though no connection to Lonza is stated in the excerpt. Additional article details were behind a sign-up/paywall and are not included in the provided text.

Total raised

$14M

Funding rounds

1

Latest round

Series B

Latest activity

Jul 2019